177,168 research outputs found
Data set from Gorla R, De Marco F, Morganti S, Finotello A, Brambilla N, Testa L, Agnifili ML, Tusa M, Auricchio F, Bedogni F. Transcatheter aortic valve implantation with the Portico and Evolut R bioprostheses in patients with elliptic aortic annulus. EuroIntervention. 2020 Apr 3;15(18):e1588-e1591. doi: 10.4244/EIJ-D-19-00115. PMID: 31186219.
Data set from Gorla R, De Marco F, Morganti S, Finotello A, Brambilla N, Testa L, Agnifili ML, Tusa M, Auricchio F, Bedogni F. Transcatheter aortic valve implantation with the Portico and Evolut R bioprostheses in patients with elliptic aortic annulus. EuroIntervention. 2020 Apr 3;15(18):e1588-e1591. doi: 10.4244/EIJ-D-19-00115. PMID: 31186219
Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma
Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time
A dexamethasone, melphalan, actinomycin-D and cytarabine chemotherapy protocol as a rescue treatment for feline lymphoma
Nineteen cats with relapsed high-grade/large-cell lymphoma were treated with dexamethasone, melphalan, actinomycin-D and cytarabine (DMAC). All cats had received Cyclophosphamide, Vincristine, Prednisolone (COP) as first-line chemotherapy and most cats had received at least 2 prior rescue agents with 14 of 19 having received both epirubicin and lomustine. Five cats (26%) exhibited a response (defined as an improvement or resolution of tumour-associated clinical signs/tumour volume, or complete/partial response) to chemotherapy though no patients received more than 2 cycles of DMAC. Most cats tolerated the protocol well though 3 patients exhibited Veterinary Cooperative Oncology Group (VCOG) grade 4 neutropenia and 1 patient exhibited grade 4 thrombocytopenia. The median progression-free survival and overall survival from starting DMAC were 14 and 17 days respectively. There is still an unmet need for successful rescue chemotherapy protocol for cats with relapsed lymphoma. [Correction added on 02 November 2017, after first online publication: The expansion for the term DMAC was previously incorrect and has been corrected in this current version.]
About this title - Meandering Streamflows: Patterns and Processes across Landscapes and Scales
Lymph node histology for the assessment of residual neoplastic disease in canine mast cell tumours: does the presence of metachromatic granules always identify mast cells?
Abstract not availabl
Internal and external parasitic infections in captive psittacine birds
Parakeets and parrots can be infected by several parasitic species that may be either primary or opportunistic pathogens and may be responsible for mild or severe clinical forms of disease (Greiner and Ritchie 1994, Doneley 2009). Some psittacine parasitic species are host specific, while others can infect a wide range of animals—including humans (Tsai and others 1992, Fayer 2010). The main aim of this study was the evaluation of the prevalence of ectoparasites and endoparasites in captive psittacine birds living in Italy
Cytological grading of canine cutaneous mast cell tumours: is haematoxylin and eosin staining better than May-Grünwald–Giemsa?
No abstract availabl
- …
